Kissei Halts Amiprilose Development

20 March 1995

Kissei Pharmaceutical has reported that it is to stop developing amiprilose HCl, an antirheumatic agent it licensed from US company Greenwich Pharmaceuticals.

The company states that the results of double-blind clinical trials in chronic rheumatoid arthritis patients revealed that the agent's effects failed to meet expectations. As a consequence of these results, it appears that the agent may not meet the standards required and so development of the drug has been halted.

- Meantime, Kissei has entered into an agreement with Wakunaga Pharmaceutical for the development and marketing of WK-1492-2K, a new non-competitive angiotensin II receptor anatagonist.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight